TY - JOUR
T1 - Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance
AU - Khot, Vishwajeet M.
AU - Salunkhe, Ashwini B.
AU - Pricl, Sabrina
AU - Bauer, Joanna
AU - Thorat, Nanasaheb D.
AU - Townley, Helen
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2021/3
Y1 - 2021/3
N2 - Cancer cell resistance to chemotherapeutics (chemoresistance) poses a significant clinical challenge that oncology research seeks to understand and overcome. Multiple anticancer drugs and targeting agents can be incorporated in nanomedicines, in addition to different treatment modalities, forming a single nanoplatform that can be used to address tumor chemoresistance. Nanomedicine-driven molecular assemblies using nucleic acids, small interfering (si)RNAs, miRNAs, and aptamers in combination with stimuli-responsive therapy improve the pharmacokinetic (PK) profile of the drugs and enhance their accumulation in tumors and, thus, therapeutic outcomes. In this review, we highlight nanomedicine-driven molecular targeting and therapy combination used to improve the 3Rs (right place, right time, and right dose) for chemoresistant tumor therapies. Nanomedicines with molecular-targeting functionality ensure the efficient delivery of chemotherapeutic cargoes into the tumor microenvironment to overcome chemoresistance.
AB - Cancer cell resistance to chemotherapeutics (chemoresistance) poses a significant clinical challenge that oncology research seeks to understand and overcome. Multiple anticancer drugs and targeting agents can be incorporated in nanomedicines, in addition to different treatment modalities, forming a single nanoplatform that can be used to address tumor chemoresistance. Nanomedicine-driven molecular assemblies using nucleic acids, small interfering (si)RNAs, miRNAs, and aptamers in combination with stimuli-responsive therapy improve the pharmacokinetic (PK) profile of the drugs and enhance their accumulation in tumors and, thus, therapeutic outcomes. In this review, we highlight nanomedicine-driven molecular targeting and therapy combination used to improve the 3Rs (right place, right time, and right dose) for chemoresistant tumor therapies. Nanomedicines with molecular-targeting functionality ensure the efficient delivery of chemotherapeutic cargoes into the tumor microenvironment to overcome chemoresistance.
UR - http://www.scopus.com/inward/record.url?scp=85098494132&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2020.12.016
DO - 10.1016/j.drudis.2020.12.016
M3 - Review article
C2 - 33359624
AN - SCOPUS:85098494132
SN - 1359-6446
VL - 26
SP - 724
EP - 739
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 3
ER -
